Combination therapy for cervical cancer
Author Information
Author(s): Sugiyama T, Nishida T, Kumagai S, Nishio S, Fujiyoshi K, Okura N, Yakushiji M, Hiura M, Umesaki N
Primary Institution: Kurume University School of Medicine
Hypothesis
The study evaluates the response rate and toxicity of irinotecan and cisplatin in neoadjuvant chemotherapy for locally advanced cervical cancer.
Conclusion
The combination of irinotecan and cisplatin is a promising and well-tolerated treatment for locally advanced cervical cancer.
Supporting Evidence
- Three patients showed complete response (13%) and 15 showed partial response (65%).
- The overall response rate was 78%.
- Stable disease was observed in four cases (17%) and progressive disease in one (4%).
- Diarrhoea and grade 3 or 4 neutropenia were observed in 10% and 75% of treatment cycles respectively.
- There were no therapy-related deaths.
Takeaway
Doctors tested a new medicine for women with a type of cervical cancer, and it worked well for many of them without causing too many bad side effects.
Methodology
A phase II study was conducted with patients receiving irinotecan and cisplatin in a neoadjuvant setting.
Limitations
The median time to failure and median survival time have not yet been reached.
Participant Demographics
Median age of participants was 59 years, with previously untreated stage Ib2, IIb, or IIIb squamous cell carcinoma.
Statistical Information
Confidence Interval
95% confidence interval 58–90%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website